Hand Eczema Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Novartis

Hand Eczema Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Novartis
DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema.

DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema, historical and forecasted epidemiology as well as the Hand Eczema market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hand Eczema Market Forecast

 

Some of the key facts of the Hand Eczema Market Report: 

  • The Hand Eczema market size was valued approximately USD 11 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • “Toctino (alitretinoin) is the only drug currently licenced to treat people with hand eczema. It is recommended for use in people with severe chronic Hand Eczema that is refractory to treatment with powerful topical corticosteroids. It is commercially accessible in numerous EU nations, Canada, and South Korea
  • The US experienced the biggest number of Hand eczema instances in 2021, approximately 26,000,000 while Spain experienced the lowest number roughly 4,000,000
  • Hand eczema affected approximately 11,000,000 men and 16,000,000 women in the United States in 2021, and it is predicted that prevalence will rise and reach up to 11,555,000 men and 16,800,000 women, respectively, by 2032.
  • Key Hand Eczema Companies: GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Novartis, Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, ACO Hud Nordic AB, Bayer, and others
  • Key Hand Eczema Therapies: Delgocitinib, ASN002, Dupilumab, betamethasone valerate, LEO 124249, Zarzenda Dupilumab, alitretinoin, and others
  • The Hand Eczema epidemiology based on gender analyzed that Hand Eczema is more prevalent in males as compared to the female population
  • The Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hand Eczema pipeline products will significantly revolutionize the Hand Eczema market dynamics.

 

Hand Eczema Overview

One of the most typical varieties of eczema and one of the most prevalent skin illnesses globally is hand dermatitis, sometimes referred to as hand eczema. Although it can affect other regions of the hand, it primarily affects the palms. Hand eczema can range in severity from extremely minor to severe, and its course can be either acute or chronic, causing long-term impairment.

 

Get a Free sample for the Hand Eczema Market Report –

https://www.delveinsight.com/sample-request/hand-eczema-market

 

Hand Eczema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hand Eczema Epidemiology Segmentation:

The Hand Eczema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hand Eczema
  • Prevalent Cases of Hand Eczema by severity
  • Gender-specific Prevalence of Hand Eczema
  • Diagnosed Cases of Episodic and Chronic Hand Eczema

 

Download the report to understand which factors are driving Hand Eczema epidemiology trends @ Hand Eczema Epidemiology Forecast

 

Hand Eczema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hand Eczema market or expected to get launched during the study period. The analysis covers Hand Eczema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hand Eczema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hand Eczema Therapies and Key Companies

  • Delgocitinib: Leo Pharma/ Japan Tobacco Inc.
  • ASN002: Asana Biosciences
  • Dupilumab: Regeneron/Sanofi

 

Discover more about therapies set to grab major Hand Eczema market share @ Hand Eczema Treatment Market

 

Hand Eczema Market Strengths

  • Widespread prevalence of the disease
  • Development of disease-specific treatments and novel therapeutic drug classes such as JAK inhibitors is likely to boost the market growth

 

Hand Eczema Market Opportunities

  • The emerging drugs have a significant opportunity, as there are no disease-specific approved therapies for the treatment of hand eczema in the United States
  • The current management of the disease includes only symptomatic treatments and does not treat the underlying cause of the disease

 

Scope of the Hand Eczema Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hand Eczema Companies: GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Novartis, Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, ACO Hud Nordic AB, Bayer, and others
  • Key Hand Eczema Therapies: Delgocitinib, ASN002, Dupilumab, betamethasone valerate, LEO 124249, Zarzenda Dupilumab, alitretinoin, and others
  • Hand Eczema Therapeutic Assessment: Hand Eczema current marketed and Hand Eczema emerging therapies
  • Hand Eczema Market Dynamics: Hand Eczema market drivers and Hand Eczema market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema Market Access and Reimbursement 

 

To know more about Hand Eczema companies working in the treatment market, visit @ Hand Eczema Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Hand Eczema Market Report Introduction

2. Executive Summary for Hand Eczema

3. SWOT analysis of Hand Eczema

4. Hand Eczema Patient Share (%) Overview at a Glance

5. Hand Eczema Market Overview at a Glance

6. Hand Eczema Disease Background and Overview

7. Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hand Eczema 

9. Hand Eczema Current Treatment and Medical Practices

10. Hand Eczema Unmet Needs

11. Hand Eczema Emerging Therapies

12. Hand Eczema Market Outlook

13. Country-Wise Hand Eczema Market Analysis (2019–2032)

14. Hand Eczema Market Access and Reimbursement of Therapies

15. Hand Eczema Market Drivers

16. Hand Eczema Market Barriers

17.  Hand Eczema Appendix

18. Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services